AFM
RAPT

Anson Funds Management’s RAPT Therapeutics RAPT Stock Holding History

Anson Funds Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,371
Closed -$217K – 294
2020
Q4 		$217K Buy
+1,371
New +$298K 0.04% 153

Other funds holding RAPT

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Anson Funds Management's RAPT Position: Q1 2021 in Review

Anson Funds Management sold out of RAPT Therapeutics (RAPT) in Q1 2021, closing a stake of 1,371 shares — an estimated $217K sold.

Anson Funds Management first reported a position in RAPT in Q4 2020 and held it in 1 quarter. The position peaked at $217K in Q4 2020. 78 funds tracked by Wall St. Rank hold RAPT as of Q1 2021.

  • Anson Funds Management reported no remaining RAPT Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Anson Funds Management sold 1,371 RAPT Therapeutics shares in Q1 2021, an estimated $217K.
  • Anson Funds Management first reported a position in RAPT Therapeutics in Q4 2020 and held it in 1 quarter.
  • Anson Funds Management's RAPT Therapeutics position peaked at $217K in Q4 2020.
  • 78 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.